Nikhilesh Singh, Ph.D., Co-founder and CEO of DIMERx, has more than 25 years of leadership experience in the development and commercialization of pharmaceutical products, including OTC and prescription drugs. He is the primary inventor on several U.S. and international patents that cover products ranging from OTC (Vicks® Formula 44), prescription (Intermezzo®), and new chemical entities, including DIMERx’s novel dimer therapeutics. Dr. Singh founded DIMERx in 2022 and OrphoMed in 2014 to develop drugs based on a proprietary dimer technology platform. Previously, Dr. Singh founded Transcept Pharmaceuticals to develop, launch, and commercialize Intermezzo®, a proprietary, novel sublingual tablet for the treatment of insomnia. Dr. Singh has raised over $100M in private financing with his prior two companies. Dr. Singh is a Fellow of the American College of Clinical Pharmacology and earned a Ph.D. in Pharmaceutical Sciences from the University of Alberta, Canada.